[Chemotherapy with imipenem/cilastatin for severe infections accompanied by malignant hematological disorders].

Abstract

The clinical and bacteriological efficacy of imipenem/cilastatin (IPM/CS) was evaluated in 30 cases of serious infections associated with hematological malignancies. 1. Among 28 evaluable cases, excellent efficacy was obtained in 6 cases and good effectiveness in 10 cases, resulting in a high clinical efficacy rate (57.1%). The clinical effectiveness of IPM/CS was not dependent on neutrophil count in peripheral blood. A 53.8% efficacy rate was observed in 26 cases which had received pretreatment with other antibiotics. 2. Antibacterial activities of IPM/CS have so far been evaluated against organisms isolated in 20 of 28 cases: 2 strains of coagulase-negative Staphylococcus, 2 strains of methicillin-resistant Staphylococcus aureus, 2 strains of Enterococcus faecalis, 9 strains of Enterobacter cloacae, and 8 other strains. 3. Among 3 evaluable cases treated with IPM/CS alone, response was good in 1 case. Among 25 patients receiving IPM/CS in combination with an aminoglycoside or a penicillin, the efficacy rate was 60%. 4. Five patients had IPM/CS-related adverse events; nausea and vomiting in 2 cases, seizures in 1 case, small increases in GOT and GPT in 2 cases, and the appearance of casts in urine sediment in 1 case. These patients, however, tolerated the complete course of therapy with IPM/CS except the 2 cases with nausea and vomiting. These results indicate that chemotherapy with IPM/CS is effective for the treatment of severe infectious diseases accompanied by hematological disorders.

• Authors: Y Fujii, Y Inoue, Y Hiroshige, K Kaku, T Kaneko
• Journal: The Japanese journal of antibiotics (Jpn J Antibiot) Vol. 46 Issue 3 Pg. 259-68 (Mar 1993) ISSN: 0368-2781 [Print] Japan
• PMID: 8510323 (Publication Type: Journal Article)

Chemical References

• Anti-Bacterial Agents
• Drug Combinations
• Cilastatin
• Imipenem
• Cilastatin, Imipenem Drug Combination

Topics

• Adolescent
• Adult
• Aged
• Anti-Bacterial Agents (administration & dosage, pharmacokinetics, therapeutic use)
• Bacterial Infections (drug therapy, etiology, metabolism)
• Cilastatin (administration & dosage, pharmacokinetics, therapeutic use)
• Cilastatin, Imipenem Drug Combination
• Drug Combinations
• Female
• Hematologic Diseases (complications)
• Humans
• Imipenem (administration & dosage, pharmacokinetics, therapeutic use)
• Immunocompromised Host
• Leukocyte Count
• Male
• Middle Aged
• Neutrophils